A Study of LY2409021 Formulations in Healthy Participants
Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure how much of the new LY2409021 tablet formulations get
into the blood stream and how long it takes the body to get rid of them, compared to the
current LY2409021 capsule formulation. In addition, the safety and tolerability of both the
new and current formulations will be evaluated. Information about any side effects that may
occur will also be collected. The study has two parts. Each participant may enroll in one
part only. The study will last up to 8 weeks for each participant. Screening is required
prior to the start of the study.